News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|December 1, 2012

A 10-year-old girl with generalized, scaly rash

The worried parents of a health 10-year-old girl ask you to evaluate her for a total-body red rash associated with scaling and edema.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Weekly review: Formula recall, FDA warning for bassinet, and more

Weekly review: Formula recall, FDA warning for bassinet, and more

ByMorgan Ebert, Executive Editor

June 19th 2026

Cadrenal plans FDA rare pediatric disease request for tecarfarin in Kawasaki disease

ByBenjamin P. Saylor

June 19th 2026

Empowering underserved children through representation, health literacy, and trusted content | Image credit: The Doctor Is In

Empowering underserved children through representation, health literacy, and trusted content

ByJosé Morey, MD,Joel Bervell, MD

June 19th 2026

FDA approves generic baloxavir marboxil for flu treatment, prophylaxis

ByBenjamin P. Saylor

June 18th 2026

Spinal muscular atrophy pharmacotherapy: Getting an earlier start | Image Credit: © Rochu_2008 - stock.adobe.com.

Spinal muscular atrophy pharmacotherapy: Getting an earlier start

ByLauren Prack, PharmD

June 18th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Chronicity, Symptom Variability, and Treatment Expectations in Pediatric Functional Constipation and IBS-C

Weekly review: Formula recall, FDA warning for bassinet, and more

Empowering underserved children through representation, health literacy, and trusted content

Spinal muscular atrophy pharmacotherapy: Getting an earlier start

Doxecitine/doxribtimine cuts mortality risk in early-onset TK2d, new data show